Children are at risk of developing adverse drug reactions (ADRs),1 yet few are reported through postmarketing surveillance schemes monitoring safety in this vulnerable population.2 We therefore developed an active surveillance system targeting New Zealand paediatricians to enhance serious ADR notifications in children aged <16 years. A priori, paediatricians were given written case definitions of serious ADRs, which they then notified to the New Zealand Paediatric Surveillance Unit (NZPSU) using standard methodologies described elsewhere.
展开▼
